Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Desmopressin (DDAVP) vs Octreotide (Sandostatin)
An educational, source-based comparison of Desmopressin (DDAVP) and Octreotide (Sandostatin) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic vasopressin analog for diabetes insipidus and nocturnal enuresis.
Synthetic analog of arginine vasopressin with enhanced antidiuretic activity and negligible vasopressor effect. Acts on renal V2 receptors to increase water reabsorption; also increases factor VIII and vWF release.
- Central diabetes insipidus
- Primary nocturnal enuresis
- Hemophilia A
- von Willebrand disease type 1
- • FDA-approved.
- • Risk of hyponatremia — limit fluids around dosing.
Synthetic somatostatin analog for acromegaly and neuroendocrine tumors.
An 8-amino-acid synthetic analog of somatostatin that binds somatostatin receptors (primarily SSTR2 and SSTR5), suppressing growth hormone, glucagon, insulin, and several gastrointestinal hormones. Longer half-life than native somatostatin enables therapeutic use.
- Acromegaly
- Carcinoid syndrome
- VIPomas
- Variceal bleeding
- Neuroendocrine tumors
- • FDA-approved.
- • Gallstones, hyperglycemia, GI upset are common adverse effects.
Desmopressin (DDAVP) vs Octreotide (Sandostatin) — Key differences
- Class: Desmopressin (DDAVP) is classified as Vasopressin Analog · Hormonal, while Octreotide (Sandostatin) is Somatostatin Analog · Oncology.
- Primary research focus: Desmopressin (DDAVP) — central diabetes insipidus; Octreotide (Sandostatin) — acromegaly.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.